Drug Trial Radar · NCT06594146
Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)
Last checked: Nov 19, 2026Latest source record: Apr 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
62
Actual
Start
Nov 11, 2024
Primary completion
Dec 30, 2025
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Keymed Biosciences Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and initial efficacy of CM313 (SC) injection in patients with primary immune thrombocytopenia.
Conditions
- Primary Immune Thrombocytopenia
Interventions
CM313 injectionBiological
CM313
placeboOther
placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventTime frame: Up to Week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Hematology & Blood Diseases Hospital
Tianjin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.